Head-to-head evidence
Isatuximab vs SCTC21C
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Isatuximab
Marketed by Sanofi
NCT02990338 · Phase 3 · completed
Participants were randomized 1:1 to isatuximab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone alone, but the study was open-label rather than double-blind. The primary clinical endpoint, progression-free survival, was met: median survival was 11.53 versus 6.47 months, with a hazard ratio of 0.596 and p=0.0005.
Next expected readout: November 2026 · NCT06517017 (registry estimate)
SCTC21C
Developed by Sinocelltech Group Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07297329 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Isatuximab's landscape · SCTC21C's landscape